Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice

Figures & data

Figure 1 Changes in BCVA ETDRS letters during the study period.

Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

Table 1 Changes in BCVA in 29 study eyes from 15 patients with DME

Time points	BCVA ETDRS letters				P-value
	Mean (SD)	95% CI	Crude difference
			Mean (SD)	95% CI
Baseline	47.3 (14.2)	41.9 to 52.7
Intravitreal aflibercept
Visit 2 (5 months)	60.3 (14.0)	55.9 to 65.7	13.0 (5.9)	10.7 to 15.2	<0.001
Visit 3 (7 months)	60.8 (13.8)	55.5 to 66.0	13.4 (6.8)	10.9 to 16.0	<0.001
Visit 4 (9 months)	60.7 (14.0)	55.4 to 66.0	13.4 (7.0)	10.7 to 6.1	<0.001
Visit 5 (12 months)	62.2 (13.8)	57.0 to 67.5	14.9 (6.5)	12.5 to 17.4	<0.001
Visit 3 vs visit 2			0.48 (4.9)	−1.3 to 2.4	0.602
Visit 4 vs visit 3			−0.03 (6.1)	−2.4 to 2.3	0.975
Visit 5 vs visit 4			1.5 (4.2)	−0.09 to 3.1	0.063

Abbreviations: BCVA, best-corrected visual acuity; DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 2 Changes in central macular thickness from baseline to 12 months after treatment with intravitreal aflibercept.

Table 2 Changes in central macular thickness in 29 study eyes from 15 patients with DME

Time points	Central macular thickness (μm)				P-value
	Mean (SD)	95% CI	Crude difference
			Mean (SD)	95% CI
Baseline	460.5 (111.8)	417.9 to 503.0
Intravitreal aflibercept
Visit 2 (5 months)	278.7 (47.7)	260.6 to 296.9	−181.8 (120.5)	−227.6 to −135.9	<0.001
Visit 3 (7 months)	273.9 (48.5)	255.4 to 292.4	−186.6 (108.6)	−227.9 to −145.3	<0.001
Visit 4 (9 months)	256.3 (50.3)	237.2 to 275.5	−204.1 (124.8)	−251.6 to −156.7	<0.001
Visit 5 (12 months)	229.0 (43.8)	212.3 to 245.6	−231.5 (126.6)	−279.7 to −183.3	<0.001
Visit 3 vs visit 2			−4.8 (45.1)	−22.0 to 12.3	0.569
Visit 4 vs visit 3			−17.5 (34.4)	−30.6 to −4.5	0.010
Visit 5 vs visit 4			−27.4 (35.0)	−40.7 to −14.1	0.001

Abbreviation: DME, diabetic macular edema.